Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) has issued an update.
MaxCyte, Inc., a non-UK issuer, has announced a change in its major holdings due to an acquisition or disposal of voting rights by BlackRock, Inc. As of March 17, 2025, BlackRock’s total voting rights in MaxCyte have increased to 7.71%, up from a previous 7.66%. This adjustment reflects BlackRock’s strategic positioning and influence within MaxCyte, potentially impacting the company’s governance and decision-making processes.
More about MaxCyte
YTD Price Performance: -22.84%
Average Trading Volume: 40,922
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £260.3M
See more insights into MXCT stock on TipRanks’ Stock Analysis page.